WO2004037166A3 - Guanidines therapeutiques - Google Patents

Guanidines therapeutiques Download PDF

Info

Publication number
WO2004037166A3
WO2004037166A3 PCT/US2003/028950 US0328950W WO2004037166A3 WO 2004037166 A3 WO2004037166 A3 WO 2004037166A3 US 0328950 W US0328950 W US 0328950W WO 2004037166 A3 WO2004037166 A3 WO 2004037166A3
Authority
WO
WIPO (PCT)
Prior art keywords
guanidines
therapeutic
ires
infections
viral
Prior art date
Application number
PCT/US2003/028950
Other languages
English (en)
Other versions
WO2004037166A2 (fr
Inventor
Elizabeth Anne Jefferson
Punit Seth
Dale E Robinson Jr
Michael Todd Migawa
Richard H Griffey
Eric Edward Swayze
Original Assignee
Isis Pharmaceuticals Inc
Elizabeth Anne Jefferson
Punit Seth
Dale E Robinson Jr
Michael Todd Migawa
Richard H Griffey
Eric Edward Swayze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc, Elizabeth Anne Jefferson, Punit Seth, Dale E Robinson Jr, Michael Todd Migawa, Richard H Griffey, Eric Edward Swayze filed Critical Isis Pharmaceuticals Inc
Priority to AU2003298582A priority Critical patent/AU2003298582A1/en
Publication of WO2004037166A2 publication Critical patent/WO2004037166A2/fr
Publication of WO2004037166A3 publication Critical patent/WO2004037166A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne en partie des dérivés de guanidine représentés par la formule (I) ou des formes de sel de ceux-ci qui répondent aux normes pharmaceutiques, des compositions de ces composés et des utilisations de ceux-ci associées, par exemple, à l'inhibition de la traduction induite par IRES. Cette invention concerne aussi le traitement d'infections virales ou d'autres infections.
PCT/US2003/028950 2002-09-17 2003-09-16 Guanidines therapeutiques WO2004037166A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003298582A AU2003298582A1 (en) 2002-09-17 2003-09-16 Therapeutic guanidines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41159802P 2002-09-17 2002-09-17
US60/411,598 2002-09-17

Publications (2)

Publication Number Publication Date
WO2004037166A2 WO2004037166A2 (fr) 2004-05-06
WO2004037166A3 true WO2004037166A3 (fr) 2005-01-06

Family

ID=32176445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028950 WO2004037166A2 (fr) 2002-09-17 2003-09-16 Guanidines therapeutiques

Country Status (2)

Country Link
AU (1) AU2003298582A1 (fr)
WO (1) WO2004037166A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2007022964A2 (fr) * 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Composes guanidine a substitution hetaryl et utilisation en tant que partenaires de liaison pour des recepteurs de 5-ht5
EP2474526A3 (fr) 2006-12-26 2012-07-25 Lantheus Medical Imaging, Inc. Ligands pour l'imagerie de l'innervation cardiaque
AU2009282574B2 (en) 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020245A (en) * 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734488A1 (fr) 2008-08-20 2010-02-25 Southern Research Institute Derives de pyridine et pyrimidine substituees par azo et leur utilisation dans le traitement d'infections virales
EP2326627A1 (fr) 2008-08-20 2011-06-01 Schering Corporation Dérivés de pyridine et pyrimidine substituées et leur utilisation dans le traitement d'infections virales
BR112012028806B1 (pt) 2010-05-11 2021-01-19 Lantheus Medical Imaging, Inc. Sal ascorbato de um composto para imagiologia, seu uso para a imagiologia médica ecomposição que o compreende
TWI700268B (zh) 2011-09-09 2020-08-01 美商藍瑟斯醫學影像公司 用於合成及使用造影劑之組合物、方法及系統

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880932A (en) * 1983-03-04 1989-11-14 Bayer Aktiengesellschaft Substituted guanidine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880932A (en) * 1983-03-04 1989-11-14 Bayer Aktiengesellschaft Substituted guanidine derivatives

Also Published As

Publication number Publication date
AU2003298582A8 (en) 2004-05-13
WO2004037166A2 (fr) 2004-05-06
AU2003298582A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
WO2003053368A3 (fr) Derives de chalcone et leur utilisation dans le traitement de maladies
MXPA03005464A (es) Agentes antivirales.
WO2002062290A3 (fr) Agents antiviraux constitues de 2-methylbenzimidazole substitue heterocyclique
WO2008142055A3 (fr) Agents antiviraux
WO2004005286A3 (fr) Inhibiteurs viraux
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
WO1998056761A3 (fr) Derives de benzimidazole
WO2003053344A3 (fr) 2-methyl-benzimidazole substitues en tant qu'agents antiviraux du virus respiratoire syncytial
GB0114286D0 (en) Nucleoside Derivatives
WO2003000695A8 (fr) Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases
WO2005028479A3 (fr) Derives de purine servant a inhiber la replication du vih
EP2431379A3 (fr) Inhibiteurs du VHC
WO2008054454A3 (fr) Dérivés hétérocycliques contenant de l'azote, compositions pharmaceutiques, et leurs procédés d'utilisations en tant qu'agents antiviraux
WO2002088124A3 (fr) Composes therapeutiques
WO2006011050A3 (fr) Derives de pyridine
WO2001066564A3 (fr) Inhibiteurs de gamma-sécrétase
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
NO20045042L (no) 7-aryl -3,9-diazabicyklo (3.1.1)non-6-en-derivater og deres anvendelse som renin. inhibitorer ved behandling av hypertensjon, kardiovaskulaere og nyresykdommer
WO2003053359A3 (fr) 1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
WO2003047520A3 (fr) Inhibiteurs de facteur xa a aminomethyle substitue
MXPA03010761A (es) Combinaciones farmaceuticas.
WO2004043362A3 (fr) Composes d'acyl guanidine et utilisation
WO2007075572A3 (fr) Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90
MXPA04006041A (es) Antivirales de piridoquinoxalina.
WO2004037166A3 (fr) Guanidines therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP